Empowering Care,
One Heart at a Time

Elucid is a medical technology company that develops AI to see invisible features of cardiovascular risk.

The company is dedicated to developing a clinical platform to help physicians deliver CCTA-guided personalized care by providing a more precise view of atherosclerosis, the root cause of cardiovascular disease.

Our Mission Statement

Elucid’s mission is to predict and personalize the prevention of heart attacks and strokes.

At Elucid, we focus on enabling efficient and transparent clinical insights to help usher in the next generation of CCTA-guided, personalized coronary artery disease care. We develop AI tools to see invisible features of risk and guide personalized, precise treatment based on a detailed analysis of patients’ atherosclerotic disease. Elucid’s platform transforms CT images into a dynamic, interactive map of disease, providing a more precise view of atherosclerosis – the root cause of cardiovascular disease – to help physicians personalize care based on a patient’s individual anatomy.

A smiling couple walks arm-in-arm through a vibrant outdoor market full of fresh vegetables and flowers.

Elucid Leadership

Andrew Miller Chief Technology Officer & SVP, Engineering

Andrew Miller

Chief Technology Officer & SVP, Engineering
Windi Hary Chief Regulatory & Quality Officer

Windi Hary

Chief Regulatory & Quality Officer
Amy Kruglak SVP, People & Leadership Development

Amy Kruglak

SVP, People & Leadership Development
Amir Ahmadi, MD Lead Scientific Advisor

Amir Ahmadi, MD

Lead Scientific Advisor

News, Media & Thought Leadership

Stay informed with the latest updates, insights, and conversations from Elucid.
Type

Elucid Moves into New Headquarters in Preparation for Commercial Launch

Elucid today announced it has moved its headquarters to 399 Boylston Street in the heart of Boston’s Back Bay neighborhood.

Elucid Raises $80 Million in Series C Round Led by Elevage Medical Technologies

Investment will drive commercialization and expansion of AI-powered non-invasive diagnostic tools to help evaluate cardiovascular risk
Windi Hary Chief Regulatory & Quality Officer

Elucid Appoints Windi Hary to Lead Regulatory Affairs and Quality Management

Elucid has hired Windi Hary as senior vice president (SVP) of regulatory affairs and quality management.
Scott Huennekens, portrait

Elucid Names Scott Huennekens Executive Chairman of the Board

Elucid today announced that it has named Scott Huennekens executive chairman of its board of directors.
Andrew Miller Chief Technology Officer & SVP, Engineering

Andrew Miller Joins Elucid as Chief Technology Officer

Elucid has hired Andrew Miller as its chief technology officer (CTO).
Curved modern building with many windows, set against a clear blue sky with a small white cloud.

Where to Find Us: Upcoming Events

Washington Hilton – Washington, DC – March 7-10, 2026

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

Stay in Touch

Subscribe to our newsletter for the latest clinical, product and regulatory updates.

Eight people in an office sit and stand together, smiling and making heart shapes with their hands.